RE: Undervalued18 Sep 2020 13:15
Lets just remind ourselves that additionally to the upcoming IBS and Covid therapeutics we are already moving on to Phase II part B for our cancer treatment after a great result announced in August.
In 12 patients with metastatic renal cell carcinoma (mRCC) and metastatic non-small cell lung cancer (mNSCLC), the combination of MRx0518 with KEYTRUDA achieved a disease control rate (DCR) of 42%, with five of 12 patients experiencing a clinically meaningful benefit from the combination.
If I am not mistaken they were hoping for a 10% improvement to show that the therapy was not futile. So 42% was a great result and we are now recruiting to test on a much larger scale of 30 patients per tumour type.
So where will the SP be if IBS, Covid and Cancer therapies are all successful. My guess we wont have a SP as we will be bought out by one of the big boys plain and simple.